The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies.
Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at North Carolina State University that focused on Cas3 proteins, which devour DNA Pac-Man-style, rather than edit it like the more
Read More At Article Source | Article Attribution
The post Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies appeared first on RocketNews | Top News Stories From Around the Globe.